A randomised study to evaluate the impact of malignant ascites on well-being and the role of breathing exercises in delaying the reaccumulation of recurrent ascites

Submission date	Recruitment status	Prospectively registered
19/08/2002	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
19/08/2002	Completed	Results
Last Edited	Condition category	[] Individual participant data
31/10/2019	Cancer	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

A randomised study to evaluate the impact of malignant ascites on well-being and the role of breathing exercises in delaying the reaccumulation of recurrent ascites

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Ovary cancer

Interventions

Following the first ascitic tap patients are randomised to either:

- 1. Group A: No initial intervention, on recurrence requiring a second ascitic tap patients are taught breathing exercises and required to wear a form of abdominal binder. Treatment to continue until reaccumulation of ascites.
- 2. Group B: Patients are taught breathing exercises and required to wear a form of abdominal binder. On recurrence requiring a second ascitic tap patients are given daily diuretic therapy with frusemide and spironolactone until reaccumulation of ascites.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1992

Completion date

01/05/1997

Eligibility

Key inclusion criteria

- 1. Recurrent abdominal ascites that are a result of relapsed primary resistant cancer of the ovary
- 2. The ascites is asymptomatic and requires drainage
- 3. Patients must not be in sub-acute or complete bowel obstruction
- 4. Performance status <3
- 5. Life expectancy of at least 12 weeks
- 6. No longer receiving chemotherapy
- 7. Adequate haematological profile and biochemistry

Participant type(s)

Patient

Age group

Not Specified

Sex

Female

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1992

Date of final enrolment

01/05/1997

Locations

Countries of recruitment

England

United Kingdom

Study participating centre MRC Clinical Trials Unit London United Kingdom

Sponsor information

Organisation

NW1 2DA

Smith and Nephew Foundation (UK)

Sponsor details

15 Adam Street London United Kingdom WC2N 6LA

Sponsor type

Industry

Website

http://www.snfoundation.org.uk

ROR

https://ror.org/03agge938

Funder(s)

Funder type

Research organisation

Funder Name

North West Thames Research and Development (UK)

Funder Name

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration